Updated clinical guideline for human papillomavirus vaccine : the Korean Society of Gynecologic Oncology guidelines
Copyright © 2021. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology..
Since the human papillomavirus (HPV) vaccine guidelines were developed by the Korean Society of Gynecologic Oncology (KSGO) in 2011, 2016, and 2019, several recent studies on the efficacy and safety of HPV vaccines in middle-aged women and men have been reported. Furthermore, there has been an ongoing debate regarding the efficacy of the HPV vaccine in women with prior HPV infection or who have undergone conization for cervical intraepithelial neoplasia (CIN). We searched and reviewed studies on the efficacy and safety of the HPV vaccine in middle-aged women and men and the efficacy of the HPV vaccine in patients infected with HPV and those who underwent conization for CIN. The KSGO updated their guidelines based on the results of the studies included in this review.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Journal of gynecologic oncology - 32(2021), 6 vom: 07. Nov., Seite e94 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cho, Hyun-Woong [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Female |
|---|
| Anmerkungen: |
Date Completed 08.12.2021 Date Revised 07.12.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3802/jgo.2021.32.e94 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332469387 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332469387 | ||
| 003 | DE-627 | ||
| 005 | 20231225215634.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3802/jgo.2021.32.e94 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1108.xml |
| 035 | |a (DE-627)NLM332469387 | ||
| 035 | |a (NLM)34708596 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cho, Hyun-Woong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Updated clinical guideline for human papillomavirus vaccine |b the Korean Society of Gynecologic Oncology guidelines |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.12.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology. | ||
| 520 | |a Since the human papillomavirus (HPV) vaccine guidelines were developed by the Korean Society of Gynecologic Oncology (KSGO) in 2011, 2016, and 2019, several recent studies on the efficacy and safety of HPV vaccines in middle-aged women and men have been reported. Furthermore, there has been an ongoing debate regarding the efficacy of the HPV vaccine in women with prior HPV infection or who have undergone conization for cervical intraepithelial neoplasia (CIN). We searched and reviewed studies on the efficacy and safety of the HPV vaccine in middle-aged women and men and the efficacy of the HPV vaccine in patients infected with HPV and those who underwent conization for CIN. The KSGO updated their guidelines based on the results of the studies included in this review | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Female | |
| 650 | 4 | |a Male | |
| 650 | 4 | |a Middle Aged | |
| 650 | 4 | |a Papillomavirus Vaccines | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 7 | |a Papillomavirus Vaccines |2 NLM | |
| 700 | 1 | |a Min, Kyung-Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Kwon, Sang-Hoon |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Kidong |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Sunghoon |e verfasserin |4 aut | |
| 700 | 1 | |a Seong, Seok Ju |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Yong Jung |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Keun Ho |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Shin-Wha |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Jeong-Won |e verfasserin |4 aut | |
| 700 | 1 | |a Ju, Woong |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Young Tae |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Jae Kwan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of gynecologic oncology |d 2008 |g 32(2021), 6 vom: 07. Nov., Seite e94 |w (DE-627)NLM188802258 |x 2005-0399 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2021 |g number:6 |g day:07 |g month:11 |g pages:e94 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3802/jgo.2021.32.e94 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2021 |e 6 |b 07 |c 11 |h e94 | ||